Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Przemyslaw Twardowski, MD

SWOG Cancer Research Network

Intervention

Erlotinib Hydrochloride(drug)

Enrollment

55 enrolled

Eligibility

All sexes

Timeline

2012 – 2017

Study locations (30)

• University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States
• Kaiser Permanente-Anaheim, Anaheim, California, United States
• Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
• Kaiser Permanente-Bellflower, Bellflower, California, United States
• Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
• Mills-Peninsula Medical Center, Burlingame, California, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Kaiser Permanente Hospital, Fontana, California, United States
• Kaiser Permanente - Harbor City, Harbor City, California, United States
• Kaiser Permanente-Irvine, Irvine, California, United States
• Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
• Los Angeles County-USC Medical Center, Los Angeles, California, United States
• USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Papillary renal cell carcinoma

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT05411081
  Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT05096390
  Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
  Centre Leon Berard
• ACTIVE NOT RECRUITINGPHASE3NCT05043090
  Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
  AstraZeneca

See all trials for Papillary renal cell carcinoma →